phrykt

Kymera Therapeutics, Inc. (KYMR): who owns it and who trades it

As of Nov 16, 2026, KYMR insiders reported 270 open-market sales worth $473M and 2 purchases worth $172M in the last 12 months, with 44% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bruce Booth (Director), with $226M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Kymera Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KYMR

274 funds and institutions reported KYMR shares worth $11.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
Baker Bros. Advisors LP10.5%
Avoro Capital Advisors LLC9.1%
T. Rowe Price Associates8.6%
T. Rowe Price Investment Management, Inc.7.6%
BlackRock, Inc.6.7%
Bvf Inc4.7%
Wellington Management Group LLP4.5%
Vanguard Portfolio Management LLC3.6%
Siren, L.L.C.3.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)12.35M15.01%$1.4B+6%
Baker Bros. Advisors LP8.66M10.52%$993MNo change
Avoro Capital Advisors LLC7.47M9.09%$857MNo change
T. Rowe Price Associates7.11M8.65%$816M+17%
T. Rowe Price Investment Management, Inc.6.26M7.61%$718M+14%
BlackRock, Inc.5.54M6.73%$635M+9%
Bvf Inc3.87M4.71%$444M-30%
Wellington Management Group LLP3.68M4.47%$421M-6%
Vanguard Portfolio Management LLC2.99M3.64%$343M+4%
Siren, L.L.C.2.94M3.57%$337M-8%
Vanguard Capital Management LLC2.93M3.56%$336M+2%
Atlas Venture Life Science Advisors, LLC2.85M3.46%$327M-38%
State Street Corp2.74M3.33%$314M+15%
Geode Capital Management, LLC1.82M2.21%$208M+10%
Capital Research Global Investors1.39M1.69%$159M-17%
Goldman Sachs Group Inc1.19M1.44%$136M+34%
UBS Group AG1.01M1.23%$116M-2%
Alliancebernstein L.P.981,5211.19%$81.8M+11%
Driehaus Capital Management LLC919,2331.12%$105M-12%
Merck & Co., Inc.772,1650.94%$88.5MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KYMR insiders reported $172M of open-market purchases and $473M of sales. 44% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$172M
2 trades, 1 people
Sales, 12 months
$473M
270 trades, 11 people
Sales under a 10b5-1 plan
44%
Share of sale value
Latest trade
Oct 1, 2026
Filed Oct 1, 2026

Purchases and sales by month

$379M$379MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 1, 2026Nello MainolfiCEOSale plan3,525$111.44$393KForm 4
Oct 1, 2026Nello MainolfiCEOSale plan5,506$112.42$619KForm 4
Oct 1, 2026Nello MainolfiCEOSale plan4,876$113.24$552KForm 4
Oct 1, 2026Nello MainolfiCEOSale plan7,601$114.43$870KForm 4
Oct 1, 2026Nello MainolfiCEOSale plan8,230$115.40$950KForm 4
Oct 1, 2026Nello MainolfiCEOSale plan262$116.12$30.4KForm 4
Sep 4, 2026Brian AdamsChief Legal OfficerSale1,209$115.55$140KForm 4
Sep 4, 2026Brian AdamsChief Legal OfficerSale3,025$116.81$353KForm 4
Sep 4, 2026Brian AdamsChief Legal OfficerSale2,137$117.57$251KForm 4
Jul 7, 2026Nello MainolfiCEOSale50,000$119.00$6MForm 4
Jul 1, 2026Noah GoodmanChief Business OfficerSale3,389$114.29$387KForm 4
Jul 1, 2026Nello MainolfiCEOSale1,883$112.80$212KForm 4
Jul 1, 2026Nello MainolfiCEOSale6,626$113.98$755KForm 4
Jul 1, 2026Nello MainolfiCEOSale44,050$115.69$5.1MForm 4
Jul 1, 2026Nello MainolfiCEOSale24,105$114.96$2.8MForm 4
Jul 1, 2026Nello MainolfiCEOSale3,336$116.56$389KForm 4
Jun 30, 2026Bruce N. JacobsCFOSale1,100$112.79$124KForm 4
Jun 30, 2026Bruce N. JacobsCFOSale4,110$114.19$469KForm 4
Jun 30, 2026Bruce N. JacobsCFOSale51,375$114.77$5.9MForm 4
Jun 30, 2026Bruce N. JacobsCFOSale1,700$111.57$190KForm 4
Jun 30, 2026Bruce N. JacobsCFOSale1,500$110.54$166KForm 4
Jun 30, 2026Bruce N. JacobsCFOSale7,971$115.82$923KForm 4
Jun 30, 2026Bruce N. JacobsCFOSale3,200$117.70$377KForm 4
Jun 30, 2026Bruce N. JacobsCFOSale6,153$116.99$720KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan10,848$108.28$1.2MForm 4
Jun 29, 2026Bruce BoothDirectorSale plan7,968$109.75$874KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan7,723$110.67$855KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan770$105.78$81.5KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan2,133$106.63$227KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan2,698$107.76$291KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan1,498$108.28$162KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan1,104$109.75$121KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan1,078$110.67$119KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan130$111.20$14.5KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan19,419$107.76$2.1MForm 4
Jun 29, 2026Bruce BoothDirectorSale plan14,798$106.63$1.6MForm 4
Jun 29, 2026Bruce BoothDirectorSale plan5,549$105.78$587KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan934$111.20$104KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan10,658$108.28$1.2MForm 4
Jun 29, 2026Bruce BoothDirectorSale plan7,833$109.75$860KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan157$111.20$17.5KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan1,199$110.67$133KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan7,602$110.67$841KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan907$111.20$101KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan1,688$108.28$183KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan1,239$109.75$136KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan5,471$105.78$579KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan14,613$106.63$1.6MForm 4
Jun 29, 2026Bruce BoothDirectorSale plan19,093$107.76$2.1MForm 4
Jun 29, 2026Bruce BoothDirectorSale plan848$105.78$89.7KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan2,318$106.63$247KForm 4
Jun 29, 2026Bruce BoothDirectorSale plan3,024$107.76$326KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan28,296$107.57$3MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan231,007$108.14$25MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan32,624$109.79$3.6MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan11,277$110.49$1.2MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan10,366$111.51$1.2MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan555$112.49$62.4KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan14,913$113.97$1.7MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan27,951$114.94$3.2MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan6,821$115.69$789KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan12,181$117.09$1.4MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan22,046$117.85$2.6MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan12,390$118.66$1.5MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan3,958$107.57$426KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan32,402$108.14$3.5MForm 4
Jun 26, 2026Bruce BoothDirectorSale plan4,562$109.79$501KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan1,579$110.49$174KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan1,442$111.51$161KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan78$112.49$8.8KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan2,083$113.97$237KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan3,896$114.94$448KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan952$115.69$110KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan1,701$117.09$199KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan3,069$117.85$362KForm 4
Jun 26, 2026Bruce BoothDirectorSale plan1,729$118.66$205KForm 4
Jun 26, 2026Biotechnology Value Fund Ii Lp +9DirectorSale837,914$106.50$89.2MForm 4
Jun 26, 2026Biotechnology Value Fund Ii Lp +9DirectorSale51,858$106.50$5.5MForm 4
Jun 26, 2026Biotechnology Value Fund Ii Lp +9DirectorSale113,289$106.50$12.1MForm 4
Jun 26, 2026Biotechnology Value Fund Ii Lp +9DirectorSale627,597$106.50$66.8MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan305$128.69$39.3KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan46$129.61$6KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan37,179$119.71$4.5MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan112,299$120.66$13.5MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan40,774$121.38$4.9MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan4,977$122.67$611KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan10,860$123.62$1.3MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan11,711$124.61$1.5MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan3,716$125.82$468KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan1,609$126.71$204KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan25,075$127.37$3.2MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan2,197$128.69$283KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan337$129.61$43.7KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan5,144$119.71$616KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan15,660$120.66$1.9MForm 4
Jun 25, 2026Bruce BoothDirectorSale plan5,689$121.38$691KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan698$122.67$85.6KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan1,517$123.62$188KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan1,639$124.61$204KForm 4
Jun 25, 2026Bruce BoothDirectorSale plan522$125.82$65.7KForm 4

Latest 100 of 272 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bruce BoothDirector–$226MJun 29, 2026
Biotechnology Value Fund Ii LpDirector–$174MJun 26, 2026
Felix BakerDirector, 10% owner$172M–Dec 11, 2025
Nello MainolfiChief Executive Officer, Director–$35MOct 1, 2026
Jeremy G ChadwickChief Operating Officer–$15.6MMay 27, 2026
Bruce N. JacobsChief Financial Officer–$9.5MJun 30, 2026
Jared GollobChief Medical Officer–$5.3MMar 4, 2026
Pamela EspositoDirector–$3.1MMar 20, 2026
Noah GoodmanChief Business Officer–$2.2MJul 1, 2026
Elena RidloffDirector–$1.3MMay 11, 2026
Brian AdamsChief Legal Officer–$744KSep 4, 2026
Jeffrey W. AlbersDirector–$449KDec 8, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KYMR short interest

Moderate short interest. 9.8% of KYMR shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 16%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.40M KYMR shares were sold short, 9.8% of the shares outstanding, down 8.4% from the report before. At the average daily volume of 800,703 shares, buying them all back would take about 10.5 trading days (days to cover).

Shares short, % of all shares

9.84%May 15Oct 3013.1%

Days to cover

10.5May 15Oct 3023.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.40M9.84%-8%800,70310.5
Oct 15, 20269.17M11.03%-7%920,93810.0
Sep 30, 20269.91M11.92%-6%828,02812.0
Sep 15, 202610.53M12.66%+2%652,85916.1
Aug 31, 202610.37M12.47%-0%616,31916.8
Aug 14, 202610.38M12.49%+4%744,55413.9
Jul 31, 20269.98M12.00%+1%552,03618.1
Jul 15, 20269.90M12.04%-2%674,87014.7
Jun 30, 202610.15M12.33%+2%1.92M5.3
Jun 15, 20269.96M12.11%-1%639,04515.6
May 29, 202610.10M12.28%+1%490,78520.6
May 15, 202610.00M12.16%+3%469,88521.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Kymera Therapeutics company events

Kymera Therapeutics filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jul 27, 2026LeadershipJared Gollob, M.D., communicated his intention to retire from his role as Chief Medical Officer of Kymera Therapeutics, Inc. and submitted his resignation on July 27, 2026. Filing
  4. Jun 25, 2026AnnouncementThe Company announced that it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis. Filing
  5. Jun 24, 2026VoteReported shareholder vote results. Filing
  6. Jun 8, 2026LeadershipJeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer on June 5, 2026. Filing
  7. Apr 30, 2026ResultsReleased financial results. Filing
  8. Mar 27, 2026RulesChanged its bylaws or articles. Filing
  9. Feb 26, 2026AgreementKymera Therapeutics, Inc. entered into a Sales Agreement, with TD Securities (USA) LLC with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate… Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Jan 13, 2026ResultsReleased financial results. Filing
  12. Dec 10, 2025AgreementKymera Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters listed in Schedule… Filing
  13. Dec 8, 2025AnnouncementShared information with investors. Filing
  14. Dec 8, 2025AnnouncementThe Company announced the results from the Company’s BroADen Phase 1b AD patient clinical trial of KT-621, its first-in-class, oral STAT6 degrader medicine. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Kymera Therapeutics financials

Famous investors that hold KYMR

2 of the 50 well-known investors we track reported holding KYMR in their latest 13F filing. The largest position is Ken Fisher's, worth $36.1M.

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026323,219$36.1M0.0%+2439%
Steve Cohen · Point72 Asset ManagementQ3 2026211,218$23.6M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KYMR in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock, Inc.13G/A6.6%
Oct 27, 2026BlackRock, Inc.13G/A6.6%

Questions about Kymera Therapeutics, Inc. (KYMR) stock

Who owns the most KYMR stock?

The largest reported owner of Kymera Therapeutics, Inc. (KYMR) is FMR LLC (Fidelity), with 15.0% of the company. In total, 274 funds and institutions reported holding KYMR at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are KYMR insiders buying or selling?

In the last 12 months, KYMR insiders reported 2 open-market purchases worth $172M and 270 sales worth $473M. The latest trade was on Oct 1, 2026. See every trade.

What is the short interest in KYMR?

As of Oct 30, 2026, 8.40M KYMR shares were sold short, 9.8% of the shares outstanding, down 8.4% from the report before. At the average daily volume of 800,703 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.

Which famous investors hold KYMR?

2 of the 50 well-known investors we track reported KYMR in their latest 13F filing, including Ken Fisher, Steve Cohen. The largest position is worth $36.1M. See all holders.

Executive pay

Kymera Therapeutics's chief executive was paid a total of $8.5M for the year ended Dec 31, 2025, down 45% from $15.4M the year before. In the last 12 months, Kymera Therapeutics's executives and directors bought $172M of stock on the open market and sold $299M.

Chief executive, total pay$8.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$27.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.